CoChat

Second-generation antipsychotics for anxiety disorders

Depping, Anna M, Komossa, Katja, Kissling, Werner, Leucht, Stefan · 2010 · Cochrane Database of Systematic Reviews
Cited by 86

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Anxiety disorders are common and disabling conditions, with a lifetime prevalence of 17% in the general population. Due to high rates of treatment resistance, there is interest in new pharmacological treatment options such as second-generation antipsychotics. OBJECTIVES: To evaluate the efficacy and tolerability of second-generation antipsychotics as monotherapy or adjunctive treatment for people with anxiety disorders. SEARCH STRATEGY: The Cochrane Depression, Anxiety and Neurosis Group's controlled trial registers (CCDANCTR-Studies and CCDANCTR-References) were searched up to 21 July 2010. The author team ran complementary searches on ClinicalTrials.gov. SELECTION CRITERIA: We included all randomised trials (RCTs) comparing second-generation antipsychotic drugs with placebo, benzodiazepines, pregabalin or antidepressants. Participants were people with generalised anxiety disorder, panic disorder and specific phobias including social phobia. DATA COLLECTION AND ANALYSIS: Two authors extracted data independently. For dichotomous data we calculated odds ratios (OR) and their 95% confidence intervals (CI). For continuous data we calculated mean differences (MD) based on a random-effects model. MAIN RESULTS: The review currently includes eleven RCTs with 4144 participants on three second-generation antipsychotics (olanzapine, quetiapine, risperidone). Nine studies investigated the effects of second-generation antipsychotics in generalised anxiety disorder, only two studies investigated the effects in social phobia. There were no studies on panic disorder or any other primary anxiety disorder.Seven studies investigated the effects of quetiapine. Participants with generalised anxiety disorder responded significantly better to quetiapine than to placebo (4 RCTs, N = 2265, OR = 2.21, 95% CI 1.10 to 4.45). However, they were more likely to drop out due to adverse events, to gain weight, to suffer from sedation or to suffer from extrapyramidal side effects. When quetiapine was compared with antidepressants, there was no significant difference in efficacy-related outcomes, but more participants in the quetiapine groups dropped out due to adverse events, gained weight and feeling sedated. Only two very small studies with a total of 36 participants examined olanzapine and found no difference in response to treatment. Two trials compared adjunctive treatment with risperidone with placebo and found no difference in response to treatment. AUTHORS' CONCLUSIONS: We identified eligible trials on quetiapine, risperidone and olanzapine. The available data on olanzapine and risperidone are too limited to draw any conclusions. Monotherapy with quetiapine seems to be efficacious in reducing symptoms of generalised anxiety disorder and this effect may be similar to that of antidepressants. However, quetiapine's efficacy must be weighed against its lower tolerability.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd008120.pub2

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 43

  1. Barnett, 2002, Efficacy of olanzapine in social anxiety disorder: a pilot study, Journal of Psychopharmacology, 16, 365, 10.1177/026988110201600412 · DOI · Paper page
  2. Brawman-Mintzer, 2005, Adjunctive risperidone in generalized anxiety disorder: a double blind, placebo-controlled study, Journal of Clinical Psychiatry, 66, 1321, 10.4088/JCP.v66n1016 · DOI · Paper page
  3. Pandina, 2007, Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, placebo-controlled, randomized trial, Psychopharmacology Bulletin, 40, 41
  4. Pollack, 2006, Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study, Biological Psychiatry, 59, 211, 10.1016/j.biopsych.2005.07.005 · DOI
  5. Simon, 2008, Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings, Psychopharmacology, 197, 675, 10.1007/s00213-008-1087-x · DOI
  6. Vaishnavi, 2007, Quetiapine as a monotherapy for social anxiety disorder: a placebo controlled study, Progress in Neuropsychopharmacology & Biological Psychiatry, 31, 1464, 10.1016/j.pnpbp.2007.06.027 · DOI
  7. Adson, 2004, Preliminary experience with adjunctive risperidone in patients receiving selective serotonin reuptake inhibitors, Depression and Anxiety, 19, 121, 10.1002/da.10137 · DOI · Paper page
  8. Adson, 2005, Treatment of anxiety symptoms with adjunctive aripiprazole in depressed patients taking serotonin reuptake inhibitors, Journal of Affective Disorders, 86, 99, 10.1016/j.jad.2004.11.007 · DOI
  9. Menza, 2007, An open label trial of aripiprazole augmentation for treatment resistant generalized anxiety disorder, Journal of Clinical Psychopharmacology, 27, 207, 10.1097/01.jcp.0000248620.34541.bc · DOI · Paper page
  10. Prosser, 2009, A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomised, single-blind study, BMC Psychiatry, 9, 25, 10.1186/1471-244X-9-25 · DOI · Paper page
  11. Sepede, 2006, Olanzapine augmentation in treatment resistant panic disorder: a 12 week fixed-dosed open-label-trial, Journal of Clinical Psychopharmacology, 26, 45, 10.1097/01.jcp.0000195108.01898.17 · DOI · Paper page
  12. Simon, 2006, An open label trial of risperidone augmentation for refractory anxiety disorders, Journal of Clinical Psychiatry, 67, 381, 10.4088/JCP.v67n0307 · DOI · Paper page
  13. Wilner, 2002, The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery, Journal of Clinical Psychopharmacology, 22, 206, 10.1097/00004714-200204000-00016 · DOI
  14. Worthington, 2005, Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients, International Clinical Psychopharmacology, 20, 9, 10.1097/00004850-200501000-00002 · DOI · Paper page
  15. Donahue, 2009, Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia, Journal of Anxiety Disorders, 23, 362, 10.1016/j.janxdis.2008.12.004 · DOI
  16. Lohoff, 2010, Ziprasidone treatment of refractory gneralized anxiety disorder : a placebo-controlled, double-blind study, Journal of Clinical Psychopharnmacology, 30, 185, 10.1097/JCP.0b013e3181d21951 · DOI · Paper page
  17. American Psychiatric Association, 1980, Diagnostic and Statistical Manual of Mental Disorders, 3rd edition (DSM III)
  18. American Psychiatric Association, 1987, Diagnostic and Statistical Manual of Mental Disorders, 3rd edition - revised (DSM-III-R)
  19. American Psychiatric Association, 1994, Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV)
  20. Arnt, 1998, Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence, Neuropsychopharmacology, 18, 63, 10.1016/S0893-133X(97)00112-7 · DOI · Paper page
  21. Bland, 1997, Statistics notes. Trials randomised in clusters, BMJ, 315, 600, 10.1136/bmj.315.7108.600 · DOI · Paper page
  22. Correll, 2004, Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of one-year studies, American Journal of Psychiatry, 161, 414, 10.1176/appi.ajp.161.3.414 · DOI · Paper page
  23. Davidson, 1997, The Brief Social Phobia Scale: a psychometric evaluation, Psychological Medicine, 27, 161, 10.1017/S0033291796004217 · DOI · Paper page
  24. Der-Simonian, 1986, Meta-analysis in clinical trials, Controlled Clinical Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  25. Gao, 2006, Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: A review, Journal of Clinical Psychiatry, 67, 1327, 10.4088/JCP.v67n0902 · DOI · Paper page
  26. Gulliford, 1999, Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994, American Journal of Epidemiology, 149, 876, 10.1093/oxfordjournals.aje.a009904 · DOI · Paper page
  27. Guy, 1976, Clinical Global Impressions - ECDEU Asessment Manual Psychopharmacology (DHEW Publ No ADM 76-338)
  28. Hamilton, 1959, The assessment of anxiety states by rating, British Journal of Medical Psychology, 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  29. Hamilton, 1960, A rating scale of depression, Journal of Neurology, 23, 56
  30. Heres, 2006, Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine, American Journal of Psychiatry, 163, 185, 10.1176/appi.ajp.163.2.185 · DOI · Paper page
  31. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  32. Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008] The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org 2008 · DOI · Paper page
  33. Ipser, 2006, Pharmacotherapy augmentation strategies in treatment resistant augmentation disoders, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005473.pub2 · DOI · Paper page
  34. Ipser, 2009, Pharmacotherapy for anxiety disorder in children and adolescents, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005170.pub2 · DOI · Paper page
  35. Kessler, 1994, Lifetime and 12-month prevalence of DSM-III psychiatric disorders in the United States, Archives of General Psychiatry, 51, 975, 10.1001/archpsyc.1994.03950010008002 · DOI · Paper page
  36. Komossa, 2009, Second-generation antipsychotic drugs for obsessive compulsive disorder, Cochrane Database of Systematic Reviews
  37. Montgomery, 1979, A new depression scale designed to be sensitive to change, British Journal of Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  38. Newcomer, 2005, Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review, CNS Drugs, 19, 1, 10.2165/00023210-200519001-00001 · DOI · Paper page
  39. Raj, 1987, Medical evaluation of panic attacks, Journal of Clinical Psychiatry, 48, 309
  40. Sajatovic, 2003, Treatment for mood and anxiety disorders: quetiapine and aripiprazole, Current Psychiatry Reports, 5, 320, 10.1007/s11920-003-0062-9 · DOI
  41. Stein, 2000, Pharmacotherapy for social anxiety disorder, Cochrane Database of Systematic Reviews
  42. Vital, 2007, Seroquel led antipsychotics sales in 2006, Clinical Psychiatric News, 35, 1
  43. World Health Organisation, 1992, International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10)

Cited by

See all 86

Metadata

Authors
Depping, A. M., Komossa, K., Kissling, W., & Leucht, S.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2010-12-08
Issue
12
Pages
CD008120-CD008120
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1738433183
Cited by
86
References
19
FWCI
9.59
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.